Superoxide dismutase

Drug Profile

Superoxide dismutase

Alternative Names: SI 3501

Latest Information Update: 21 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiron Corporation; Seikagaku Corporation
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Oxidoreductases
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Osteoarthritis

Most Recent Events

  • 15 May 2001 Discontinued-Preclinical for Osteoarthritis in USA (Unknown route)
  • 12 Jun 1996 A preclinical study has been added to the Rheumatic disease pharmacodynamics section
  • 21 Aug 1995 Seikagaku Corporation is developing superoxide dismutase in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top